Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
91944 trials found · Page 131 of 4598
-
New mRNA shot aims to stop shingles pain
⭐️ VACCINE ⭐️ Not yet recruitingThe study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 79 years of age.
Phase: PHASE2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 09, 2026 09:22 UTC
-
New combo therapy aims to outsmart returning hodgkin lymphoma
Disease control Not yet recruitingThis is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investiga…
Phase: PHASE2 • Sponsor: Michael Spinner, MD • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
Could Late-Stroke patients still benefit from clot removal? new trial aims to find out
Disease control Recruiting nowSELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving bette…
Phase: NA • Sponsor: Amrou Sarraj • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Could a 50-year-old drug beat dengue? new trial aims to find out.
Disease control Not yet recruitingThe goal of this study is to evaluate the efficacy and safety of emetine administered orally for symptomatic patients aged 18-65 years infected with the dengue virus. The main questions it aims to answer are: 1. Does emetine reduce 28-day mortality or progression to severe dengu…
Phase: PHASE2, PHASE3 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
School-Based malaria treatment aims to shield entire villages
Prevention Not yet recruitingThe CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the…
Phase: PHASE4 • Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Apr 30, 2026 15:51 UTC
-
Engineered immune cells take on hard-to-treat cancers in early trial
Disease control Not yet recruitingOnly enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New hope for lung cancer patients with brain tumors: drug combo trial launches
Disease control Not yet recruitingThis is a prospective, open-label, multi-center, single-arm clinical trial
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New sepsis trial aims to match treatments to Patients' unique traits
Disease control Not yet recruitingPALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological …
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
Weight-Loss drug tirzepatide may cut AFib recurrence after ablation in obese patients
Disease control Not yet recruitingThe goal of this clinical trial is to determine whether tirzepatide can reduce atrial fibrillation (AF) burden after catheter ablation in overweight or obese patients with persistent AF. It will also evaluate the effects of tirzepatide on body weight, metabolic risk factors, and …
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Radioactive therapy offers new hope for hard-to-treat kidney cancer
Disease control Not yet recruitingSummary Renal Cell Carcinoma (RCC) consists of 2% of all malignencies. RCCs are generally divided to histopathological subtypes as clear cell and non-clear cell variants. Clear cell variant responsible for the 75-80% of all RCCs. It is reported that 20-30% of RCCs are metastatic …
Phase: PHASE3 • Sponsor: Ankara University • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
Engineered immune cells take on deadly brain tumors
Disease control Not yet recruitingThis clinical study is designed to evaluate the safety and efficacy of IL13Rα2 CAR-T cells secreting anti-PD-L1 antibody in patients with recurrent malignant glioma. This trial is a multicenter, open-label, non-randomized, single-arm investigator-initiated trial (IIT). Patients w…
Phase: PHASE1 • Sponsor: Ming Yang • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New Chemo-Free cocktail aims to tackle aggressive lymphoma without harsh side effects
Disease control Not yet recruitingThis is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated May 09, 2026 09:23 UTC
-
Promising drug cocktail aims to wipe out esophageal tumors before surgery
Disease control Not yet recruitingIn the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have been suboptimal. Immune checkpoint inhibitors (ICIs) …
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
AI coach aims to close the hepatitis b treatment gap
Disease control Not yet recruitingThe World Health Organization (WHO) has set a target to eliminate viral hepatitis by 2030, aiming for a 90% diagnosis rate and an 80% treatment rate for chronic hepatitis B (CHB). However, as of 2024, only 26.1% of CHB infections globally have been diagnosed, and only 14.6% have …
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
Magnetic brain zaps could lift severe depression that drugs Can't touch
Symptom relief Not yet recruitingThis study will evaluate the efficacy and safety of a theta burst stimulation (TBS) protocol of repetitive transcranial magnetic stimulation (rTMS) in adults with treatment-resistant depression. Participants will be randomized to either antidepressant treatment plus active rTMS T…
Phase: NA • Sponsor: Jung-Sun Lee • Aim: Symptom relief
Last updated May 07, 2026 18:39 UTC
-
New CAR-T therapy aims to fight tough lymphoma
Disease control Not yet recruitingThis study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
Blood test guides throat cancer therapy in new trial
Disease control Not yet recruitingThe purpose of this study is to assess risk for HPV driven oropharyngeal cancers by using HPV blood tests and clinical features (such as tumor stage and smoking status) to determine appropriate treatment to improve survival outcomes in participants with stage I, II, or III, HPV-a…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
Second chance: experimental stroke drug aims to unblock brain arteries when first treatment fails
Disease control Not yet recruitingIschemic cerebrovascular disease is a common neurological disorder with high incidence, mortality, and disability. Early reperfusion to salvage the ischemic penumbra is the cornerstone of acute ischemic stroke (AIS) treatment. Current reperfusion strategies include intravenous th…
Phase: PHASE2 • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
Could a common antibiotic boost stroke recovery?
Disease control Not yet recruitingThe aim of this study is to assess the efficacy and safety of minocycline in improving functional outcome among patients with acute ischaemic stroke receiving intravenous thrombolysis.
Phase: PHASE3 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
Steroid shield: new hope to prevent HIV treatment complications
Prevention Not yet recruitingThis study was a multicenter, open-label, randomized controlled clinical trial designed to evaluate the efficacy and safety of glucocorticoids in preventing paradoxical immune reconstitution inflammatory syndrome (IRIS) in patients with AIDS complicated by opportunistic infection…
Phase: NA • Sponsor: Shanghai Public Health Clinical Center • Aim: Prevention
Last updated May 06, 2026 16:15 UTC